Serum apolipoprotein B measurement

Albers JJ & Marcovina SM: Standardization of apolipoprotein B and A-I measurements. Clin Chem 1989; 35(7):1357-1361.

Walldius G & Jungner I: Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med 2004; 255(2):188-205.

Gibbons RJ, Abrams J, Chatterjee K, et al: ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 2003; 41(1):159-168.

Taylor AJ, Merz CN, & Udelson JE: 34th Bethesda Conference: Executive summary--can atherosclerosis imaging techniques improve the detection of patients at risk for ischemic heart disease. J Am Coll Cardiol 2003; 41(11):1860-1862.

Talmud PJ, Hawe E, Miller GJ, et al: Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol 2002; 22(11):1918-1923.

Pearson TA: New tools for coronary risk assessment: what are their advantages and limitations. Circulation 2002; 105(7):886-892.

Gotto AM Jr, Whitney E, Stein EA, et al: Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000; 101(5):477-484.

Greenland P, Abrams J, Aurigemma GP, et al: Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. Circulation 2000; 101(1):E16-E22.

Cremer P, Nagel D, Mann H, et al: Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men. Atherosclerosis 1997; 129(2):221-230.

Lamarche B, Moorjani S, Lupien PJ, et al: Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation 1996; 94(3):273-278.

Brown G, Albers JJ, Fisher LD, et al: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323(19):1289-1298.

Reinhart RA, Gani K, Arndt MR, et al: Apolipoproteins A-I and B as predictors of angiographically defined coronary artery disease. Arch Intern Med 1990; 150(8):1629-1633.

Tietz NW (Ed): Clinical Guide to Laboratory Tests, 3rd ed. W. B. Saunders, Philadelphia, PA, 1995.